Research Points to Translational Path Toward Precision Immunotherapies for EGFR-Mutant NSCLC

Targeted Therapy Plus Immune Checkpoint Inhibitors: Research Opportunities, But No Improvement in Activity to Date

… Targeted Therapy Plus Immune Checkpoint Inhibitors: Research Opportunities, But No Improvement in Activity to Date …

Wu-Kong28 Data Support Sunvozertinib as First-Line Treatment Option for EGFR-Mutant NSCLC, Researcher Says

… as First-Line Treatment Option for EGFR-Mutant NSCLC, Researcher Says … Haleigh Behrman …

Keynote Address Explores the Future of Biomarkers in the ADC Era

… R. Hirsch outlined the current state of knowledge in ADC research, as well as what still needs to be learned. … Keynote …